Fosaprepitant

FOSAPREPITANT

Manufacturer: BluePoint Laboratories

Score: 145.0

Quick Summary

Fosaprepitant is a substance P/neurokinin-1 (NK1) receptor antagonist used in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy (HEC) and moderately emetogenic cancer chemotherapy (MEC). The recommended dosage is 150 mg administered as an intravenous infusion over 20 to 30 minutes, approximately 30 minutes prior to chemotherapy. Fosaprepitant is contraindicated in patients with hypersensitivity to any component of the product and in patients taking pimozide. The most common adverse reactions include fatigue, diarrhea, neutropenia, asthenia, anemia, and peripheral neuropathy.

Key Clinical Findings and Indications

Prevention of acute and delayed nausea and vomiting associated with HEC
Prevention of acute and delayed nausea and vomiting associated with MEC

Important Safety Information

Warning

Hypersensitivity reactions, including anaphylaxis and anaphylactic shock, have been reported

Contraindications

Hypersensitivity to any component of the product
Concurrent use with pimozide

Adverse Reactions

Fatigue
Diarrhea
Neutropenia
Asthenia
Anemia
Peripheral neuropathy

Dosing Recommendations

HEC

Adult Dose

150 mg intravenously over 20 to 30 minutes, approximately 30 minutes prior to chemotherapy

Pediatric Dose

MEC

Adult Dose

150 mg intravenously over 20 to 30 minutes, approximately 30 minutes prior to chemotherapy

Pediatric Dose

Special Population Considerations

Pregnancy

There are insufficient data on use of fosaprepitant in pregnant women to inform a drug-associated risk

Nursing Mothers

The efficacy of hormonal contraceptives may be reduced during treatment with fosaprepitant

Pediatric Use

The safety and effectiveness of fosaprepitant have not been established in patients less than 6 months of age

Geriatric Use

Use caution when dosing elderly patients as they have a greater frequency of decreased hepatic, renal, or cardiac function and concomitant disease or other drug therapy